Ovid Therapeutics Inc (OVID) Stock Price, Quote & News

Company Profile

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 661 7661

Fax: 646 661 4027

Website: www.ovidrx.com

Address:

441 Ninth Avenue, 14th Floor, New York, United States

Wedge_ Mar. 18 at 8:00 PM

Amazing day. 5 for 5: $OVID twice, $VNRX, $LNKS, $AIM 86% success rate since I started posting my entries/exits here in real time.

0 · Reply

Zipcash Mar. 18 at 7:55 PM

$OVID Problaby a offering at $1.50 by tomorrow morning ! Usually that’s it goes . Don’t forget this still phase 1 folks

0 · Reply

Achouffe Mar. 18 at 7:36 PM

$OVID Make or break?

0 · Reply

FriendOfmy Mar. 18 at 7:32 PM

$OVID Next update will be six months from now . That means no where to go but down for now

0 · Reply

FriendOfmy Mar. 18 at 7:31 PM

$OVID Unfortunately gains will be on the red soon.

0 · Reply

topstockalerts Mar. 18 at 7:02 PM

$OVID keeps getting repeat attention. That usually signals positioning ahead of potential updates.

0 · Reply

joaneegell Mar. 18 at 7:00 PM

$OVID Pleasant surprise today. I'm out but I hope that I regret selling tomorrow GLTA

0 · Reply

Merlintrader Mar. 18 at 5:24 PM

$OVID https://www.merlintrader.com/ovid-therapeutics-dd-march2026/

0 · Reply

Wedge_ Mar. 18 at 4:43 PM

$OVID Back in 2.24

0 · Reply

FriendOfmy Mar. 18 at 4:40 PM

$OVID $2.00 close .

0 · Reply

Ovid Therapeutics' New Epilepsy Trial Data Ignites Rally

Mar 18, 2026, 6:05 AM EDT - 10 hours ago

Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 18, 2026, 6:00 AM EDT - 10 hours ago

Ovid Therapeutics Announces Pricing of $60 Million Private Placement

Feb 25, 2026, 7:00 AM EST - 21 days ago

Ovid Therapeutics to Participate in Upcoming Investor Conferences

Jan 26, 2026, 11:01 PM EST - 7 weeks ago

Ovid Therapeutics: Bullish Post-PIPE With 2 Differentiated CNS Moonshots

Dec 18, 2025, 8:00 AM EST - 3 months ago

Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)

Dec 2, 2025, 7:00 AM EST - 3 months ago

Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer

Nov 12, 2025, 7:00 AM EST - 4 months ago

Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results

Oct 3, 2025, 12:52 PM EDT - 5 months ago

Ovid Therapeutics Inc. - Special Call

Oct 3, 2025, 7:05 AM EDT - 5 months ago

Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds

Oct 3, 2025, 7:00 AM EDT - 5 months ago

Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile

Aug 13, 2025, 8:00 AM EDT - 7 months ago

Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results

Jul 23, 2025, 8:30 AM EDT - 8 months ago

Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference

Jun 25, 2025, 8:00 AM EDT - 9 months ago

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

May 13, 2025, 8:00 AM EDT - 11 months ago

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 8:00 AM EST - 1 year ago

Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

Feb 27, 2025, 8:00 AM EST - 1 year ago

Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Feb 5, 2025, 8:00 AM EST - 1 year ago

Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Sep 11, 2024, 8:00 AM EDT - 1 year ago

Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth

Aug 19, 2024, 11:00 AM EDT - 1 year ago

Shareholders In Ovid Therapeutics Inc Invited To Participate In Fraud Investigation With The Schall Law Firm

Aug 18, 2024, 11:00 AM EDT - 1 year ago

Ovid Therapeutics Inc Investors Encouraged To Join Fraud Investigation With Schall Law Firm

Aug 17, 2024, 11:00 AM EDT - 1 year ago

Ovid Therapeutics Inc Shareholders Eligible To Participate In Fraud Investigation With Schall Law Firm

Aug 16, 2024, 11:00 AM EDT - 1 year ago

Ovid Therapeutics Inc Investors Invited To Join In Fraud Investigation With Schall Law Firm

Aug 15, 2024, 11:00 AM EDT - 1 year ago

Ovid Therapeutics Inc Shareholders Encouraged To Join Fraud Investigation With Schall Law Firm

Aug 14, 2024, 10:30 PM EDT - 1 year ago

Ovid Therapeutics Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm

Aug 14, 2024, 1:15 AM EDT - 1 year ago

Ovid Therapeutics Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results

Aug 12, 2024, 11:55 PM EDT - 1 year ago

Ovid Therapeutics Inc Investors Invited To Join Fraud Investigation With Schall Law Firm

Aug 9, 2024, 9:15 PM EDT - 1 year ago

Investors Of Ovid Therapeutics Inc Can Participate In Fraud Investigation With The Schall Law Firm

Aug 8, 2024, 4:00 PM EDT - 1 year ago

Investors Of Ovid Therapeutics Inc Eligible To Join Fraud Investigation With The Schall Law Firm

Aug 7, 2024, 11:30 PM EDT - 1 year ago

Investors Of Ovid Therapeutics Inc Can Join Fraud Investigation With The Schall Law Firm

Aug 6, 2024, 4:00 PM EDT - 1 year ago

Ovid Therapeutics Inc Investors Can Participate In Fraud Investigation With The Schall Law Firm

Aug 2, 2024, 10:00 AM EDT - 1 year ago

OVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law Firm

Jul 30, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics to Present at Upcoming August Investor Conferences

Jul 23, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists

Jul 1, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations

Jun 17, 2024, 8:58 AM EDT - 1 year ago

What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?

TAK

Jun 17, 2024, 6:55 AM EDT - 1 year ago

Ovid Therapeutics Reports on Takeda's Announcement of Phase 3 Topline Study Results for Soticlestat

May 14, 2024, 8:00 AM EDT - 2 years ago

Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results

May 13, 2024, 7:00 AM EDT - 2 years ago

Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Apr 9, 2024, 10:48 AM EDT - 2 years ago

Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024

Apr 4, 2024, 8:00 AM EDT - 2 years ago

Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 8, 2024, 8:00 AM EST - 2 years ago

Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results

Feb 28, 2024, 8:00 AM EST - 2 years ago

Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

Wedge_ Mar. 18 at 8:00 PM

Amazing day. 5 for 5: $OVID twice, $VNRX, $LNKS, $AIM 86% success rate since I started posting my entries/exits here in real time.

0 · Reply

Zipcash Mar. 18 at 7:55 PM

$OVID Problaby a offering at $1.50 by tomorrow morning ! Usually that’s it goes . Don’t forget this still phase 1 folks

0 · Reply

Achouffe Mar. 18 at 7:36 PM

$OVID Make or break?

0 · Reply

FriendOfmy Mar. 18 at 7:32 PM

$OVID Next update will be six months from now . That means no where to go but down for now

0 · Reply

FriendOfmy Mar. 18 at 7:31 PM

$OVID Unfortunately gains will be on the red soon.

0 · Reply

topstockalerts Mar. 18 at 7:02 PM

$OVID keeps getting repeat attention. That usually signals positioning ahead of potential updates.

0 · Reply

joaneegell Mar. 18 at 7:00 PM

$OVID Pleasant surprise today. I'm out but I hope that I regret selling tomorrow GLTA

0 · Reply

Merlintrader Mar. 18 at 5:24 PM

$OVID https://www.merlintrader.com/ovid-therapeutics-dd-march2026/

0 · Reply

Wedge_ Mar. 18 at 4:43 PM

$OVID Back in 2.24

0 · Reply

FriendOfmy Mar. 18 at 4:40 PM

$OVID $2.00 close .

0 · Reply

Mikeqb20 Mar. 18 at 4:10 PM

$OVID Nice day! Next up is $GIFT you MOFO's!

0 · Reply

Jlook Mar. 18 at 4:04 PM

$OVID VNRX going🪐

0 · Reply

topstockalerts Mar. 18 at 3:12 PM

Top Gainers PT2 $JEM $YYGH $DVLT $ATXG $OVID

0 · Reply

topstockalerts Mar. 18 at 2:47 PM

$OVID keeps getting repeat looks which hints at positioning. These names tend to reprice fast on updates.

0 · Reply

WallStKiller Mar. 18 at 2:43 PM

$OVID Very solid base for a bounce back to pre market runs. Very nice balance.

0 · Reply

creyl Mar. 18 at 2:42 PM

$OVID let's tear down that wall

0 · Reply

creyl Mar. 18 at 2:30 PM

$OVID 0.42 to 9.57

0 · Reply

notreload_ai Mar. 18 at 2:11 PM

$OVID shares climbed after swinging to a surprise Q4 profit beat and raising $60 million via PIPE financing. https://notreload.xyz/ovid-stock-surges-on-surprise-q4-profit-beat-and-60m-pipe-to-expand-ov329-into-new-seizure-indications/

0 · Reply

WallStKiller Mar. 18 at 1:51 PM

$OVID A true retrace via algo/ volume differential. I love where this is going! ❤️

0 · Reply

Wedge_ Mar. 18 at 1:48 PM

$OVID Half out 2.40

0 · Reply

creyl Mar. 18 at 1:43 PM

$OVID let's go

0 · Reply

trading_insight Mar. 18 at 1:33 PM

Watch These Today $AIM heavy volume leading early momentum $ARTL biotech staying active $OVID building steady interest $TPET energy seeing unusual flow

0 · Reply

Market Cap	140.29M
Revenue (ttm)	570,000.00
Net Income (ttm)	-26.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-4,636.84%
Debt to Equity Ratio	0.00

Volume	38,669,816
Avg Vol	1,609,596
Day's Range	N/A - N/A
Shares Out	71.21M
Stochastic %K	50%
Beta	0.25
Analysts	Strong Sell
Price Target	$4.16